Roche demonstrated a phase 3 trial success combining the CD20xCD3 bispecific antibody Lunsumio with the antibody-drug conjugate Polivy to treat large B-cell lymphoma (LBCL) patients ineligible for stem cell transplant. This regimen significantly reduced progression or death risk by 59% compared to standard chemotherapy. Median progression-free survival extended from 3.8 to 11.5 months. The trial results support global regulatory submissions and highlight a promising combination approach to overcome resistance and enhance lymphoma treatment outcomes.